GoAI
Get started
Progyny, Inc. logo

Progyny, Inc.

PGNY

NASDAQHealthcareMedical - Healthcare Plans

Open in GoAI

Previous close

$25.65

−$0.31 · -1.19%

Aug 21, 4:00 PM ET

PGNY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

77

Undervalued

Momentum

67

Gaining

Sentiment

60

Mixed

Risk resilience

75

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Industry
Medical - Healthcare Plans
Sector
Healthcare
Headquarters
US
CEO
Pete Anevski
Listed since
Oct 25, 2019
Employees
846

Market position

Day range

Current $25.65

52-week range

Current $25.65

Open
$26.145
Previous close
$25.96
Volume
1.08M
0.77× average
Average volume
1.39M
Average daily volume
Market cap
2.01B USD
Beta
1.02
Market reference 1
50-day average
$29.0472
-11.70% below average
200-day average
$23.9472
+7.11% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.1B USD
P/E (TTM)
26.44×
P/B (TTM)
4.42×
P/S (TTM)
1.53×
EV / EBITDA
20.96×
Earnings yield
2.67%
Free cash flow yield
8.76%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
24.57%
Operating margin
8.55%
Net margin
6.00%
Return on equity
11.34%
Return on assets
7.88%
Return on invested capital
9.62%

Financial health

Debt / equity
0.06×
Current ratio
2.73×
Altman Z-score
7.93
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends26%17%9%1%Gross margin, FY2021: 22.40%Gross margin, FY2022: 21.26%Gross margin, FY2023: 21.94%Gross margin, FY2024: 21.71%Gross margin, FY2025: 23.63%Operating margin, FY2021: 6.46%Operating margin, FY2022: 2.97%Operating margin, FY2023: 5.71%Operating margin, FY2024: 5.78%Operating margin, FY2025: 6.62%Net margin, FY2021: 13.14%Net margin, FY2022: 3.86%Net margin, FY2023: 5.70%Net margin, FY2024: 4.66%Net margin, FY2025: 4.54%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 22.40%. Gross margin FY2022 21.26%. Gross margin FY2023 21.94%. Gross margin FY2024 21.71%. Gross margin FY2025 23.63%. Operating margin FY2021 6.46%. Operating margin FY2022 2.97%. Operating margin FY2023 5.71%. Operating margin FY2024 5.78%. Operating margin FY2025 6.62%. Net margin FY2021 13.14%. Net margin FY2022 3.86%. Net margin FY2023 5.70%. Net margin FY2024 4.66%. Net margin FY2025 4.54%.

Income trends

Revenue

1.29B USD+10.40%

Operating income

85.28M USD+26.42%

Net income

58.52M USD+7.70%
Income trends across reported periods1.42B USD909.07M USD402.94M USD−103.19M USDRevenue, FY2021: 500.62M USDRevenue, FY2022: 786.91M USDRevenue, FY2023: 1.09B USDRevenue, FY2024: 1.17B USDRevenue, FY2025: 1.29B USDOperating income, FY2021: 32.34M USDOperating income, FY2022: 23.34M USDOperating income, FY2023: 62.18M USDOperating income, FY2024: 67.46M USDOperating income, FY2025: 85.28M USDNet income, FY2021: 65.77M USDNet income, FY2022: 30.36M USDNet income, FY2023: 62.04M USDNet income, FY2024: 54.34M USDNet income, FY2025: 58.52M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 500.62M USD. Revenue FY2022 786.91M USD. Revenue FY2023 1.09B USD. Revenue FY2024 1.17B USD. Revenue FY2025 1.29B USD. Operating income FY2021 32.34M USD. Operating income FY2022 23.34M USD. Operating income FY2023 62.18M USD. Operating income FY2024 67.46M USD. Operating income FY2025 85.28M USD. Net income FY2021 65.77M USD. Net income FY2022 30.36M USD. Net income FY2023 62.04M USD. Net income FY2024 54.34M USD. Net income FY2025 58.52M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.29B USD1.17B USD1.09B USD786.91M USD500.62M USD
Cost of goods sold984.18M USD913.86M USD849.8M USD619.59M USD388.49M USD
Gross profit304.48M USD253.36M USD238.8M USD167.33M USD112.14M USD
Selling, general, and administrative219.21M USD185.91M USD176.62M USD143.98M USD79.8M USD
Operating expenses219.21M USD185.91M USD176.62M USD143.98M USD79.8M USD
Interest income10.16M USD15.75M USD8.51M USD814K USD461K USD
Depreciation and amortization4.95M USD3.18M USD2.28M USD1.6M USD1.3M USD
Operating income85.28M USD67.46M USD62.18M USD23.34M USD32.34M USD
Net income58.52M USD54.34M USD62.04M USD30.36M USD65.77M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+0.54%
11 comparable reports
Latest EPS result
0.36
Estimate 0.33 · Beat by 7.53%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.560.40.250.09Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.12, estimate 0.11, surprise +9.09%, Beat. Q2 2025, reported May 8, 2025: actual 0.18, estimate 0.19, surprise -5.46%, Miss. Q3 2025, reported Aug 7, 2025: actual 0.2, estimate 0.17, surprise +17.65%, Beat. Q4 2025, reported Nov 6, 2025: actual 0.16, estimate 0.39, surprise -58.97%, Miss. Q1 2026, reported Feb 26, 2026: actual 0.15, estimate 0.147, surprise +2.04%, Beat. Q2 2026, reported May 7, 2026: actual 0.3, estimate 0.256, surprise +17.19%, Beat. Q3 2026, reported Aug 6, 2026: actual 0.36, estimate 0.335, surprise +7.53%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.52, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates364.53M330.94M297.35M263.76MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 298.43M USD, estimate 277.78M USD, surprise +7.43%, Beat. Q2 2025, reported May 8, 2025: actual 324.04M USD, estimate 307.86M USD, surprise +5.26%, Beat. Q3 2025, reported Aug 7, 2025: actual 332.87M USD, estimate 320.1M USD, surprise +3.99%, Beat. Q4 2025, reported Nov 6, 2025: actual 313.35M USD, estimate 299.26M USD, surprise +4.71%, Beat. Q1 2026, reported Feb 26, 2026: actual 318.4M USD, estimate 307.42M USD, surprise +3.57%, Beat. Q2 2026, reported May 7, 2026: actual 328.5M USD, estimate 326.46M USD, surprise +0.62%, Beat. Q3 2026, reported Aug 6, 2026: actual 350.51M USD, estimate 349.05M USD, surprise +0.42%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 340.64M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

20 ratings
Strong buy00%
Buy1470%
Hold630%
Sell00%
Strong sell00%

PGNY news

defenseworld.net

Bank of America Corp DE Grows Stake in Progyny, Inc. $PGNY

Bank of America Corp DE boosted its stake in shares of Progyny, Inc. (NASDAQ: PGNY) by 75.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The…

Read source
marketbeat.com

Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook

Progyny NASDAQ: PGNY CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have…

Read source
defenseworld.net

California State Teachers Retirement System Purchases 23,273 Shares of Progyny, Inc. $PGNY

California State Teachers Retirement System lifted its position in shares of Progyny, Inc. (NASDAQ: PGNY) by 30.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…

Read source
gurufocus.com

Progyny Inc (PGNY) Stock Down 4.6% -- Now Undervalued? GF Score: 93/100

On August 11, 2026, Progyny Inc (PGNY) shares fell by 4.6%, bringing the current price to $26.55. The stock has seen significant volatility, with a 52-week high

Read source
zacks.com

Boost Your Portfolio Returns With These 4 Top-Ranked Liquid Stocks

IVZ, HUBS, HNGE and PGNY make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

Read source
fool.com

Why Progyny Stock Plunged, Then Gradually Recovered Today

Progyny stock initially plummeted this morning but has steadily marched back toward even.

Read source

PGNY peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PGNY

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
112.18M
Weight
0.10%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
70.12M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
50.45M
Weight
0.03%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
46.11M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
42.46M
Weight
0.14%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
28.95M
Weight
0.06%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
26.17M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
17.76M
Weight
0.10%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28+0.61%

Continue in GoAI

Research PGNY

research.disclaimer